Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Ost

Showing results (191-200 of 334) with videos related to

Pageof 34
Sort By:
Cancer Research|June 23, 2023
Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate CancerMarija Pizurica, Maarten Larmuseau, Kim Van der Eecken, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 28, 2019
Radiation Dosimetry and Biodistribution of <sup>18</sup>F-PSMA-11 for PET Imaging of Prostate CancerSarah Piron, Kathia De Man, Nick Van Laeken, et al.
European Urology Open Science|August 2, 2021
The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) RegistryNicolaas Lumen, Elise De Bleser, Sarah Buelens, et al.
European Urology Focus|July 21, 2017
Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based SurveyRenée Bultijnck, Cristian Surcel, Guillaume Ploussard, et al.
Cancers|April 3, 2021
Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate CancerBram De Laere, Alessio Crippa, Ashkan Mortezavi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 19, 2015
Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: A 3-arm randomized phase II trialDieter Berwouts, Katrien De Wolf, Bieke Lambert, et al.
European Urology|November 5, 2018
Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic ReviewGuillaume Ploussard, Giorgio Gandaglia, Hendrik Borgmann, et al.
Journal of Translational Medicine|July 1, 2017
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic responseNora Sundahl, Katrien De Wolf, Sylvie Rottey, et al.
European Urology|July 21, 2015
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional AnalysisPiet Ost, Barbara Alicja Jereczek-Fossa, Nicholas Van As, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 9, 2022
Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysisAisling S Barry, Joelle Helou, Andrea Bezjak, et al.
Pageof 34

Showing results (191-200 of 334) with videos related to

Sort By:
Pageof 34
Cancer Research|June 23, 2023
Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate CancerMarija Pizurica, Maarten Larmuseau, Kim Van der Eecken, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 28, 2019
Radiation Dosimetry and Biodistribution of <sup>18</sup>F-PSMA-11 for PET Imaging of Prostate CancerSarah Piron, Kathia De Man, Nick Van Laeken, et al.
European Urology Open Science|August 2, 2021
The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) RegistryNicolaas Lumen, Elise De Bleser, Sarah Buelens, et al.
European Urology Focus|July 21, 2017
Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based SurveyRenée Bultijnck, Cristian Surcel, Guillaume Ploussard, et al.
Cancers|April 3, 2021
Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate CancerBram De Laere, Alessio Crippa, Ashkan Mortezavi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 19, 2015
Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: A 3-arm randomized phase II trialDieter Berwouts, Katrien De Wolf, Bieke Lambert, et al.
European Urology|November 5, 2018
Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic ReviewGuillaume Ploussard, Giorgio Gandaglia, Hendrik Borgmann, et al.
Journal of Translational Medicine|July 1, 2017
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic responseNora Sundahl, Katrien De Wolf, Sylvie Rottey, et al.
European Urology|July 21, 2015
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional AnalysisPiet Ost, Barbara Alicja Jereczek-Fossa, Nicholas Van As, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 9, 2022
Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysisAisling S Barry, Joelle Helou, Andrea Bezjak, et al.
Pageof 34